BioSpace News Archive

ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis patients.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced it is commercially launching its Omnipod DASH® Insulin Management System in additional countries.

Vizient announces that Katrina Harper , clinical pharmacy director, will present at the Food and Drug Administration’s Compounding Quality Center of Excellence Virtual Conference: Working Together for Patient Safety on Sept. 22. The conference will bring together current and future outsourcing facilities, regulators and other compounding experts and stakeholders to learn and engage on key topics and best practices.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, announced that Health Canada has approved its next generation rechargeable implantable neurostimulator for the Axonics r-SNM® System.

MiMedx Group, Inc., an industry leader in advanced wound care and a therapeutic biologics company, provided guidance regarding certain unaudited, preliminary third quarter financial results.

AdaptHealth Corp., a leading provider of home medical equipment, supplies and related services in the United States, announced the appointment of Frank J. Mullen as Chief Accounting Officer, a newly created position.

Portfolio Now Includes Ultra-Low Temperature Solutions to Meet Emerging Needs of Pharmaceutical Customers

Legend Biotech Corporation, a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced that its Board of Directors has appointed Dr. Ying Huang as interim Chief Executive Officer, effective immediately.

Only PARP Inhibitor to Improve Overall Survival Versus Enzalutamide or Abiraterone in Advanced Prostate Cancer

Patients Treated with LYNPARZA and Bevacizumab Lived Without Disease Progression or Death for a Median of 37.2 Months vs. 17.7 Months with Bevacizumab Alone Following Response to Platinum-Based Chemotherapy